ARCT
NASDAQ · Biotechnology
Arcturus Therapeutics Holdin
$7.57
+0.55 (+7.83%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 30.40M | 31.39M | 23.67M |
| Net Income | -5,676,909 | -5,088,256 | -3,711,629 |
| EPS | — | — | — |
| Profit Margin | -18.7% | -16.2% | -15.7% |
| Rev Growth | +22.0% | +5.3% | +9.7% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 51.33M | 42.41M | 50.91M |
| Total Equity | 136.87M | 148.93M | 147.38M |
| D/E Ratio | 0.38 | 0.28 | 0.35 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -6,604,338 | -7,015,778 | -5,079,230 |
| Free Cash Flow | -5,135,953 | -5,929,972 | -4,352,810 |